PTAB/USPTO Update - November 2021

PTAB/USPTO Update - November 2021

Client Alert

Authors

USPTO News

Legislation

Notices, Guidance, and Requests

Final Rules

Interim Rules

  • There are no interim rules.

Proposed Rules

  • There are no proposed rules.

PTAB Decisions

  • New Precedential PTAB Decisions
    • There are no new informative PTAB decisions.
  • New Informative PTAB Decisions
    • There are no new informative PTAB decisions.

New Requests for POP Review

There were two new requests for POP review:

  • Triplet Therapeutics, Inc. v. Board of Supervisors of LSU Agric. and Mech. Coll. (PGR2021-00059) [Notice of Receipt of POP Request issued October 5, 2021] [Petitioner requests review of Institution Decision, presenting the question of whether 35 U.S.C. § 325(d) permits the Board to deny institution of “a written description challenge presented in the petition” which “is [allegedly] the same argument as an enablement rejection raised during prosecution.”]
  • Cisco Sys., Inc. v K.Mizra LLC (IPR2021-00593, -00594) [Notice of Receipt of POP Request issued October 12, 2021] [Patent Owner requests review of Institution Decision, presenting the question of “whether Fintiv factor 2 should compare the proximity of the district court’s trial date to the projected completion of Director review, as opposed to the projected statutory deadline for a final written decision, in light of the Supreme Court’s decision in United States v. Arthrex, Inc., 141 S. Ct. 1970 (2021).”]

Requests for Director Review

  • Parties have submitted 118 requests for Director review under the USPTO’s interim process in light of the Supreme Court’s decision in U.S. v. Arthrex. Of those requests, a total of 51 have been denied, 66 are pending, and one has been withdrawn. No request has been granted.

Authors

More From This Series

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.